MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

(2020) Stephen T. Oh et al.   Blood Advances

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review

(2019) Mario Tiribelli et al.   BONE MARROW TRANSPLANTATION

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients

(2018) Maura Nicolosi et al.   LEUKEMIA

Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response

(2018) Xueping Luo et al.   Blood Cancer Journal

Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis

(2017) Juan-Carlos Hernández-Boluda et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials

(2017) Chad Gwaltney et al.   LEUKEMIA RESEARCH

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies

(2016) A. A. Zahr et al.   HAEMATOLOGICA

Alleviating anemia and thrombocytopenia in myelofibrosis patients

(2016) Francisco Cervantes et al.   Expert Review of Hematology

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies

(2016) A. A. Zahr et al.   HAEMATOLOGICA

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) A. M. Vannucchi et al.   ANNALS OF ONCOLOGY

Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis

(2015) Justyna Bartoszko et al.   Clinical Lymphoma Myeloma & Leukemia

Hepcidin-dependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation

(2014) Jacqueline M. Langdon et al.   AMERICAN JOURNAL OF HEMATOLOGY

How I treat myelofibrosis

(2014) F. Cervantes   BLOOD

Systemic Iron Homeostasis

(2013) Tomas Ganz   PHYSIOLOGICAL REVIEWS

One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience

(2012) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

(2011) R. Scherber et al.   BLOOD

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS

(2010) C. Elena et al.   HAEMATOLOGICA

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

Iron overload and toxicity: the hidden risk of multiple blood transfusions

(2009) A. Shander et al.   VOX SANGUINIS